Project Grant R43CA298696
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85251, USA
Similar Awards
- The National Cancer Institute (NCI) awarded Oraliva, Inc. a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel, low-cost, and fully integrated point-of-care (POC) gynecological screening test. The grant, awarded on September 1, 2025, with a completion date of August 31, 2026, will enable Oraliva to leverage its proprietary AI-linked cytomics-on-a-chip technology (ONC-INCYT) to create a rapid, POC diagnostic tool that can accurately...
- The federal Project Grant was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $764,448 grant was awarded to Cereus Diagnostics Corp. on August 1, 2025 to develop Lung-FAST, a rapid and cost-effective PCR-based test that can detect clinically actionable genetic mutations in lung cancer samples with high accuracy, even from small biopsy samples. The key...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,414,853 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Innotech Precision Medicine, Inc., a woman-owned small business, to develop RECOGNIZE-OPSCC. This saliva-based, point-of-care diagnostic test aims to provide rapid, non-invasive, and accurate detection of oropharyngeal squamous cell carcinoma (OPSCC). The project integrates an AI-enabled, ultraportable device with an...
- The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...
- This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- This National Science Foundation (NSF) Project Grant award for $305,000 to Innotech Precision Medicine, Inc. aims to develop and validate a portable diagnostic system that detects cancer markers for both risk and progression in saliva. The project will focus on creating a fully integrated microfluidic device that combines multiple types of biomarker detection into one enclosed cartridge. Key technical challenges to be addressed include improving sample handling consistency, ensuring even reagent...
- The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
- Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...
- The National Cancer Institute (NCI) awarded a $399,816 Project Grant to Xgenomes Corp., a minority-owned biotechnology company in Cambridge, MA, under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The purpose of the 1-year project is to further develop Xgenomes' novel DNA analysis platform that can directly measure both genetic mutations and epigenetic methylation changes with over 100x greater accuracy than current next-generation sequencing methods. The...